Compare MRTN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | PRCT |
|---|---|---|
| Founded | 1946 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | 2021 |
| Metric | MRTN | PRCT |
|---|---|---|
| Price | $17.34 | $22.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $35.44 |
| AVG Volume (30 Days) | 790.3K | ★ 1.3M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,131,455,000.00 | $308,054,000.00 |
| Revenue This Year | $2.23 | $31.34 |
| Revenue Next Year | $8.59 | $24.52 |
| P/E Ratio | $888.50 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $9.35 | $19.35 |
| 52 Week High | $18.48 | $62.17 |
| Indicator | MRTN | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 34.25 |
| Support Level | $14.31 | $22.05 |
| Resistance Level | $18.48 | $29.27 |
| Average True Range (ATR) | 0.50 | 1.67 |
| MACD | -0.10 | -0.60 |
| Stochastic Oscillator | 25.16 | 5.13 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.